Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes Journal Article


Authors: Grivas, P.; Mortazavi, A.; Picus, J.; Hahn, N. M.; Milowsky, M. I.; Hart, L. L.; Alva, A.; Bellmunt, J.; Pal, S. K.; Bambury, R. M.; O’Donnell, P. H.; Gupta, S.; Guancial, E. A.; Sonpavde, G. P.; Faltaos, D.; Potvin, D.; Christensen, J. G.; Chao, R. C.; Rosenberg, J. E.
Article Title: Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
Abstract: Background: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single-arm, open-label phase 2 study. Methods: Eligible patients with platinum-treated, advanced/metastatic disease received oral mocetinostat (at a dose of 70 mg 3 times per week [TIW] escalating to 90 mg TIW) in 28-day cycles in a 3-stage study (ClinicalTrials.gov identifier NCT02236195). The primary endpoint was the objective response rate. Results: Genomic testing was feasible in 155 of 175 patients (89%). Qualifying tumor mutations were CREBBP (15%), EP300 (8%), and both CREBBP and EP300 (1%). A total of 17 patients were enrolled into stage 1 (the intent-to-treat population); no patients were enrolled in subsequent stages. One partial response was observed (11% [1 of 9 patients; the population that was evaluable for efficacy comprised 9 of the 15 planned patients]); activity was deemed insufficient to progress to stage 2 (null hypothesis: objective response rate of ≤15%). All patients experienced ≥1 adverse event, most commonly nausea (13 of 17 patients; 77%) and fatigue (12 of 17 patients; 71%). The median duration of treatment was 46 days; treatment interruptions (14 of 17 patients; 82%) and dose reductions (5 of 17 patients; 29%) were common. Mocetinostat exposure was lower than anticipated (dose-normalized maximum serum concentration [Cmax] after TIW dosing of 0.2 ng/mL/mg). Conclusions: To the authors’ knowledge, the current study represents the first clinical trial using genomic-based selection to identify patients with urothelial cancer who are likely to benefit from selective histone deacetylase inhibition. Mocetinostat was associated with significant toxicities that impacted drug exposure and may have contributed to modest clinical activity in these pretreated patients. The efficacy observed was considered insufficient to warrant further investigation of mocetinostat as a single agent in this setting. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Keywords: urothelial carcinoma; histone deacetylase; mocetinostat; creb binding protein (crebbp); e1a binding protein p300 (ep300)
Journal Title: Cancer
Volume: 125
Issue: 4
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2019-02-15
Start Page: 533
End Page: 540
Language: English
DOI: 10.1002/cncr.31817
PUBMED: 30570744
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 March 2019 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Jonathan Eric Rosenberg
    225 Rosenberg